Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ICU Medical needleless connector receives 510(k) clearance

This article was originally published in The Gray Sheet

Executive Summary

Neutron neutral-pressure needleless connector is designed to prevent all types of blood reflux in a catheter, including line and syringe disconnection, patient vascular pressure changes caused by coughing or sneezing, as well as an IV bag running dry, the firm said Aug. 3. According to ICU Medical, the neutral-pressure design may help address FDA concerns about the safety of positive displacement needleless connectors. The agency recently said it would require nine companies - including ICU - to conduct post-market surveillance studies on their connectors to determine if they are associated with higher rates of device-associated bloodstream infections (1"The Gray Sheet" Aug. 2, 2010)

You may also be interested in...

New Products In Brief

CorMatrix Cardiovascular’s ECM

Regulatory News In Brief

Hologic panel: FDA's Radiological Devices Panel will weigh in on Hologic's Selenia Dimensions 3-D digital mammography tomosynthesis system on Sept. 24 in Gaithersburg, Md. The firm is seeking PMA approval for both screening and diagnostic indications. The panel is a long time in coming: the firm backed out of a June 2009 panel review to strengthen its case for the product, which it had originally hoped to launch in 2008. The firm most recently forecast approval late this year (1"The Gray Sheet" Feb. 8, 2010). The tomosynthesis technology is designed to address what Hologic calls the primary limitation of 2-D digital mammography, "namely, the superposition of normal breast anatomy that may mask a breast cancer.

Chloroquine ‘Approval’ For COVID-19 And The US FDA’s New Reality

Asking whether FDA’s decision to allow emergency use of two old anti-malarial drugs was ‘political’ misses the point. The issue already was political, and FDA’s action may well be the best way to keep some measure of federal control on supplies of a drug with important other uses.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts